A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms.

Jason J. Luke,Manish R. Patel,Erika Paige Hamilton,Bartosz Chmielowski,Susanna Varkey Ulahannan,Hedy L. Kindler,Shakeela Wazeen Bahadur,Philip R. Clingan,Girish Mallesara,Andrew J. Weickhardt,Scott Currence,Linzhi Xu,Sanjeev Kaul,Francine Chen,Paul A. Moore,Ezio Bonvini,Brad Sumrow,George R. Blumenschein

A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms.

2020

Jason J. Luke
Manish R. Patel
Erika Paige Hamilton
Bartosz Chmielowski
Susanna Varkey Ulahannan
Hedy L. Kindler
Shakeela Wazeen Bahadur
Philip R. Clingan
Girish Mallesara
Andrew J. Weickhardt
Scott Currence
Linzhi Xu
Sanjeev Kaul
Francine Chen
Paul A. Moore
Ezio Bonvini
Brad Sumrow
George R. Blumenschein

3004Background: MGD013 is an investigational, first-in-class, Fc-bearing bispecific tetravalent DART molecule designed to bind PD-1 and LAG-3 and sustain/restore the function of exhausted T cells. ...

Keywords:

Oncology
in patient
first in human
open label
Pathology
dose escalation
Internal medicine
Medicine
Cancer research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations